资讯

Zacks.com on MSN2 天
Sanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid
SNY and REGN's Dupixent gets FDA approval for a rare and chronic skin disease, marking its eighth approved indication for the ...
Sanofi, Regeneron Get FDA Approval for Dupixent to Treat Rare Skin Disease
The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...
PharmExec2 天
FDA Approves Regeneron, Sanofi’s Dupixent for Bullous Pemphigoid
FDA approves first targeted therapy for bullous pemphigoid (BP): Dupixent (dupilumab) becomes the first and only targeted ...
pharmaphorum2 天
Dupixent is first FDA-approved drug for rare skin disease
IL-4 and IL-13 inhibitor Dupixent (dupilumab) is the first biologic drug to show an improvement in remission and symptoms in ...
Regeneron, Sanofi Announce Positive Dupixent Results for Atopic Dermatitis
Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...
Medical Dialogues2 小时
FDA Approves Dupilumab as First Targeted Treatment for Bullous Pemphigoid
The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...
Pharmabiz1 天
Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous ...
Sanofi & Regeneron’s Dupixent receives US FDA approval to treat patients with bullous pemphigoid: Paris Saturday, June 21, 2025, 12:00 Hrs [IST] The US Food and Drug Administrat ...
Stocktwits on MSN2 天
Regeneron, Sanofi Say Their Inflammation Drug Approved By FDA For Rare Skin Disease ...
Regeneron Pharmaceuticals, Inc. (REGN) and Sanofi (SNY) on Friday announced that the U.S. Food and Drug Administration (FDA) ...
Finanznachrichten2 天
Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the U.S. as the Only ...
Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. "Dupixent has shown the potential to improve the most ...
Nasdaq2 天
Regeneron and Sanofi Announce FDA Approval of Dupixent for Treatment of Bullous Pemphigoid ...
Yancopoulos, M.D., Ph.D., Board co-Chair, President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “Dupixent has shown the potential to improve the most ...